HD5 

HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer^[1][2][3].

HD5 binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells^[1].
HD5 (20 µM) binds to regions of HPV16 L1 and L2 capsid proteins^[2].
HD5 (15 μM; 5 days) significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP^[3].
HD5 (0.1 μM) binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay^[3].
HD5 significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HD5 (ectopic expression via lentiviral transduction; ~47 pg/mL secreted in cell supernatants) significantly inhibits the oncolytic activity of PtDd-deficient adenoviruses (mut-Ad3GFP, wt-Ad5GFP) but not PtDd-producing adenovirus (wt-Ad3GFP) in CB17 mice subcutaneously injected with K562-HD5 cells, with PtDd able to reverse HD5-mediated inhibition of mut-Ad3GFP^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3582.14

C₁₄₄H₂₃₈N₅₀O₄₅S₆

798569-33-2

Ala-Thr-Cys-Tyr-Cys-Arg-Thr-Gly-Arg-Cys-Ala-Thr-Arg-Glu-Ser-Leu-Ser-Gly-Val-Cys-Glu-Ile-Ser-Gly-Arg-Leu-Tyr-Arg-Leu-Cys-Cys-Arg (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)

ATCYCRTGRCATRESLSGVCEISGRLYRLCCR (disulfide bridge:Cys3-Cys31,Cys5-Cys20,Cys10-Cys30)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444.  [Content Brief]

  [2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234.

  [3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28.